Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell has started a marketing and distribution agreement with Sanquin, the Dutch blood supply foundation. Under the terms of the agreement, Crucell will get exclusive distribution rights for Cofact.
Subscribe to our email newsletter
Cofact is Sanquin’s prothrombin complex of blood factors II, VII, IX and X which is currently in MRP (mutual recognition procedure) registration, in a number of Crucell’s key markets including Norway, Sweden, Denmark, Spain and Italy. Crucell will also have a right of first refusal for China, Korea and a number of Eastern European countries.
Ronald Brus, Crucell’s CEO, said: “This deal complements the distribution agreement that is in place with Talecris since April 2007. Both deals are in line with our protein strategy to enhance Crucell’s market presence with plasma derived products.”